Gannex Announces US IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH

Gannex Pharma Co., Ltd. announced the Investigational New Drug (IND) application approval by US FDA and initiation of global development of ASC43F, a fixed-dose combination with dual targets of thyroid hormone receptor beta and farnesoid X receptor for the treatment of non-alcoholic steatohepatitis (NASH).